The Novo Nordisk share price is up 51% over the past year, while Eli Lilly is up 84%.
The biotech sector is filled with mispriced securities after an era of easy money in 2020, according to Janus Henderson’s Agustin Mohedas.
Investor interest in companies engaged in gene-based drug development is growing, according to Invesco.
Sentiment toward biotech companies may deteriorate again if efforts to develop treatments for Covid-19 prove to be unsuccessful, according to Polar Capital.
The funds are now available to Singapore retail investors and have been submitted to the SFC for sale in Hong Kong.
The UK-based firm is the latest to join the growing number of asset managers that have launched thematic products in Asia.